A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer

Publisher： Karger

E-ISSN： 2296-5262|33|10|504-511

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.33, Iss.10, 2010-09, pp. : 504-511

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 70, Iss. 1, 2018-01 ,pp. : 40-48

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prevention and Treatment of Chemotherapy-Induced Neutropenia with the Biosimilar Filgrastim: A Non-Interventional Observational Study of Clinical Practice Patterns

By  

Oncology Research and Treatment, Vol. 38, Iss. 4, 2015-03 ,pp. : 146-152

Karger

Access to resources Recommend Favorite

Frequency of Febrile Neutropenia in Breast Cancer Patients Receiving Epirubicin and Docetaxel/Paclitaxel with Colony-Stimulating Growth Factors: A Comparison of Filgrastim or Lenograstim with Pegfilgrastim

By  

Oncology, Vol. 70, Iss. 4, 2006-10 ,pp. : 290-293

Karger

Access to resources Recommend Favorite

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 12, 2015-12 ,pp. : 2981-2988

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation

By  

TRANSFUSION, Vol. 55, Iss. 11, 2015-11 ,pp. : 2709-2713

John Wiley & Sons Inc

Access to resources Recommend Favorite